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Background: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is reported to be a prognostic
and predictive factor of alkylating chemotherapy for glioblastoma patients. Methylation specific PCR (MSP) has been
most commonly used when the methylation status of MGMT is assessed. However, technical obstacles have hampered
the implementation of MSP-based diagnostic tests. We quantitatively analyzed the methylation status of the entire
MGMT promoter region and applied this information for prognostic prediction using sequencing technology.
Methods: Between 1998 and 2012, the genomic DNA of 85 tumor samples from newly diagnosed glioblastoma
patients was subjected to bisulfite treatment and subdivided into a training set, consisting of fifty-three samples, and a
test set, consisting of thirty-two samples. The training set was analyzed by deep Sanger sequencing with a sequencing
coverage of up to 96 clones per sample. This analysis quantitatively revealed the degree of methylation of each cytidine
phosphate guanosine (CpG) site. Based on these data, we constructed a prognostic prediction system for glioblastoma
patients using a supervised learning method. We then validated this prediction system by deep sequencing with a
next-generation sequencer using a test set of 32 samples.
Results: The methylation status of the MGMT promoter was correlated with progression-free survival (PFS) in our
patient population in the training set. The degree of correlation differed among the CpG sites. Using the data from the
top twenty CpG sites, we constructed a prediction system for overall survival (OS) and PFS. The system successfully
classified patients into good and poor prognosis groups in both the training set (OS, p = 0.0381; PFS, p = 0.00122) and
the test set (OS, p = 0.0476; PFS, p = 0.0376). Conventional MSP could not predict the prognosis in either of our sets.
(training set: OS; p = 0.993 PFS; p = 0.113, test set: OS; p = 0.326 PFS; p = 0.342).
Conclusions: The prognostic ability of our prediction system using sequencing data was better than that of
methylation-specific PCR (MSP). Advances in sequencing technologies will make this approach a plausible option for
diagnoses based on MGMT promotor methylation.
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A glioblastoma (GB) is a malignant brain tumor with a
poor prognosis; the median survival time of GB patients
is less than 2 years [1]. The current standard of care for
GB patients is maximum surgical resection combined
with radiation and concomitant adjuvant temozolomide
(TMZ) therapy [2]. The long-term results of the EORTC-
NCIC CE.3 trial revealed that the 5-year survival of GB
patients approaches 10%, despite the largely poor progno-
sis [3]. Although novel drugs, such as molecular-targeted
drugs, have been developed, their survival benefit has not
been confirmed, and these molecular targeted drugs are
known to carry risks of specific adverse events [4-6]. Ac-
cordingly, it is important to identify patients who may re-
spond to conventional chemo-radiation therapy as part of
future personalized care. Although nitrosoureas were
commonly used for chemotherapy, TMZ is now used for
first-line therapy. These drugs are alkylating agents that
add an alkyl group to the O6 position of guanine,
damaging the genomic DNA of cancer cells. O6-
methylguanine-DNA methyltransferase (MGMT) removes
alkyl groups from the O6 position of guanine and plays an
important role in DNA repair [7-10]. Therefore, MGMT
expression is associated with resistance to chemothera-
peutic alkylating agents. The expression of MGMT is
controlled by epigenetic gene silencing [11-13]. The
methylation of the MGMT promoter is associated with
sensitivity to alkylating chemotherapy drugs and is recog-
nized as a prognostic factor for GB patients [14-18].
In recent years, TMZ monotherapy has been at-
tempted for elderly GB or low-grade glioma patients,
and an association between the treatment response and
the MGMT methylation status has been examined
[19,20]. These studies demonstrated that the methylation
status of MGMT is a strong predictive factor of TMZ
monotherapy outcomes in elderly GB patients, and the
clinical utility of the MGMT methylation status is in-
creasing [21,22].
Even with this accumulating clinical evidence, the im-
plementation of diagnostic tests examining the methyla-
tion status of the MGMT promoter has been difficult.
PCR-based techniques, such as methylation-specific PCR
(MSP) and quantitative MSP, are the most popular
methods of assessment [23,24]. These techniques detect
methylation sequences by sequence-specific binding of
primers, which is an indirect method and only detects a
limited number of methylation sites. DNA sequencing
(i.e., bisulfite genomic sequencing) provides more direct
information on methylation status. In this context, pyro-
sequencing is considered a good alternative. However,
the target methylation sites of pyrosequencing are also
limited [25,26]. The MGMT promoter region spans
more than one thousand base pairs and contains ap-
proximately one hundred potential methylation sites. Toassess the methylation status of the MGMT promoter, it
would be preferable to assess information from all
methylation sites and select important CpG sites with
survival analysis.
In this report, we performed deep sequencing of the
MGMT promoter region after bisulfite treatment to clar-
ify the global methylation status of the region. Because
the methylation status is not uniform in glioma tissue, it
is important to characterize the intratumor heterogen-
eity of MGMT promoter methylation. An analysis of sur-
vival data assessed the correlation between each CpG
site and the malignancy of the glioblastoma. Based on
this correlation, we built a classifier to predict the malig-
nancy of GB using deep sequencing with a next-
generation sequencer.Methods
Patient characteristics
We obtained 85 GB specimens from patients who under-
went surgical resection at Kyoto University Hospital and
related regional hospitals between 1998 and 2012. The
majority of the patients were recruited for a phase II clin-
ical trial [27], and their tissues were used for studies on
gene expression profiling [28,29]. Histological diagnoses
were established by the Kyoto University Pathology Unit
according to the criteria established by the World Health
Organization. The protocol was approved by the institu-
tional review board of Kyoto University, and written in-
formed consent was obtained from each of the patients.
All tumor specimens were immediately snap frozen upon
surgical resection and stored at −80°C until use. Tumor
specimens containing 20% or more non-tumor tissue or
necrotic areas were excluded from further analysis. The
preoperative Karnofsky performance status score of each
patient was at least 50 for each case. All patients received
radiation therapy with and without alkylating chemother-
apy postoperatively. The patient characteristics are shown
in Table 1. We divided the data matrix into two data sets:
one set consisted of 53 patients and was designated as the
training set, and the other set contained 32 patients and
was designated as the test set.DNA extraction and bisulfite treatment
Genomic DNA was extracted with the QIAamp DNA
Mini Kit (Qiagen) according to the manufacturer’s in-
structions. One nanogram of genomic DNA was sub-
jected to bisulfite treatment using the MethylEasy DNA
Bisulfite Modification Kit (Takara) in accordance with
the manufacturer’s instructions. We determined the
quality of bisulfite-treated genomic DNA by real-time
PCR of the actin gene as previously described [30]. The
outline of the procedure is schematically shown in
Additional file 1: Figure S1.
Table 1 Patients’ clinical characteristics
Sample 85








Post operative therapy VAC-feron 57
Temozolomide 14
Other ACNU regimen 4
Radiation alone 7
Other 3
Overall survival (months) 3-96 Median: 12
Progression free survival (months) 1-96 Median: 6
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Conventional MSP was performed as previously de-
scribed [31]. PCR was performed using AmpliTaq Gold
polymerase and the GeneAmp PCR system 9700 (Ap-
plied Biosystems). The sequences of the primer pairs
were 5′-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-
3′ and 5′-AACTCCACACTCTTCCAAAAACAAAACA-
3′ for unmethylated MGMT (fragment size: 93 bp) and
5′- TTTCGACGTTCGTAGGTTTTCGC -3′ and 5′-GCA
CTCTTCCGAAAACGAAACG-3′ for methylated MGMT
(fragment size: 81 bp). These sequences and the PCR pri-
mer sequences used in the further analysis were con-
structed according to the MGMT promoter sequence
(http://www.ncbi.nlm.nih.gov/nuccore/X61657.1). After an
initial incubation at 95°C for 12 min, PCR amplification
was performed with 40 cycles of 95°C for 15 sec, 59°C for
30 sec, and 72°C for 30 sec, followed by a 4-min final ex-
tension. The PCR products were electrophoresed on 2%
agarose gels and were classified as methylated if a band
with the PCR product was visualized using the methylated
primer. The experiments were performed twice to confirm
the reproducibility of the results. There were no discrep-
ancies between duplicate reactions.
Quantitative bisulfite genome sequencing (qBGS) of the
training set
For qBGS, the MGMT promoter region was amplified
by nested PCR. The sequences of the first-round PCR
primers were 5′-TGGTAAATTAAGGTATAGAGTTTT
AGG-3′ and 5′-GGTTAGGTGTTAGTGATGTT-3′. The
PCR protocol was optimized for bisulfite-treated genomic
DNA; each 10-μl reaction mixture of the modified proto-
col contained 2.5 mM MgCl2, 3% DMSO, 20 ng bisulfite-treated genomic DNA, and 1 μl of AmpliTaq Gold. After
an initial incubation at 95°C for 12 min, PCR amplification
was performed using 30 cycles of 95°C for 15 sec, 54°C for
30 sec and 72°C for 1 min, followed by a 4-min final ex-
tension. A 1-μl aliquot of the first-round PCR product was
used as the template of the second-round PCR reaction.
The sequences of the second-round PCR primers were 5′-
TGGTAAATTAAGGTATAGAGTTTTAGG-3′ and 5′-TT
GGATTAGGTTTTTGGGGTT-3′ (fragment size: 662 bp).
The genomic position is chr 10: 131,155,100-131,155,761.
The second-round PCR was performed using KOD-plus
DNA polymerase (TOYOBO) according to the manufac-
turer’s instructions with 1.5 mM MgSO4 and 3% DMSO.
After an initial incubation at 95°C for 2 min, PCR amplifi-
cation was performed with 30 cycles of 94°C for 15 sec,
58°C for 30 sec, and 68°C for 1 min. The PCR products
were purified using the MinElute PCR Purification Kit
(QIAGEN) and ligated into the pCR-Blunt plasmid using
the Zero Blunt PCR Cloning Kit (Invitrogen) and a DNA
ligation kit (Takara). MAX Efficiency DH5 Competent
Cells (Invitrogen) were used for transformations. A total
of 96 colonies of each sample were subjected to bisulfite
sequencing using a 3730xl DNA Analyzer (Applied Bio-
systems). The methylation status was analyzed with
QUMA web tools (http://quma.cdb.riken.jp/).
qBGS for the test set
For the test set, we used next-generation sequencing
(MiSeq, Illumina) instead of Sanger sequencing. The tar-
get sequence was amplified by nested PCR. PCR amplifi-
cation was performed using 40 cycles of 94°C for 30 sec,
54°C for 30 sec, and 72°C for 45 min, followed by a
4-min final extension. The sequences of the first-round
PCR primers were 5′-GGATATGTTGGGATAGTT-3′
and 5′-CCAAAAACCCCAAACCC-3′ [26]. The se-
quences of the second-round PCR primers were 5′-
GGATATGTTGGGATAGTT-3′ and 5′- AAATAAATAA
AAATCAAAAC-3′ (fragment size: 216 bp). The anneal-
ing temperature was 48°C in the second-round PCR. The
PCR product was attached with an adapter for MiSeq
plus, consisting of an eight- or six-base index. The pooled
PCR library of the test set samples was sequenced by
paired-end sequencing with a MiSeq sequencer. Paired-
end reads were aligned to a C-to-T converted reference se-
quence of the MGMT promoter region using BWA [32].
We used SAMtools to obtain the per-base coverage (pileup
files) and counted non-bisulfite converted sites [33].
Statistical analysis
Statistical analyses were performed using the free statis-
tics software R (http://www.r-project.org/). Overall sur-
vival (OS) and progression-free survival (PFS) were
defined as the period from surgery to death and from
surgery to radiological detection of tumor progression,
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the criteria of the Brain Tumor Registry committee
(Japan), which includes: a 25% increase in tumor size,
the appearance of new lesions, or the obvious deterior-
ation of the patient due to a mass effect or perifocal
edema (in Table 1).
Results
Quantitative bisulfite genome sequencing of the training
set
Bisulfite sequencing was performed to fully analyze the
methylation status of the MGMT promoter region. Due
to intratumor heterogeneity, the methylation status of
individual cells is not identical, even within a single gli-
oma tissue. To clarify this heterogeneity, we performed
quantitative bisulfite sequencing and obtained data from
25 to 81 molecules (median, 51) from each sample. This
approach is referred to as quantitative bisulfite genome
sequencing (qBGS). The 662-bp fragment subjected to












1  vs 2 0.892
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1  vs 4 0.0533
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Figure 1 Clustering of the training set and survival analysis. Unsuperv
hierarchical cluster analysis of the methylation of the MGMT promoter in 5
(red), moderately methylated; cluster 3 (green), slightly methylated; cluster
the results obtained using MSP. The gray column indicates methylated, and
was performed between all combinations of the four cluster subgroups. Fo
cluster 1 and cluster 4 (p = 0.00491) and between cluster 2 and cluster 4 (p
between any combination of the four clusters, but there was a trend towalocated within the CpG island of the MGMT promoter
region was excluded from further analysis. The methyla-
tion proportion at each CpG site was calculated as the
fraction of clones with a methylated C at that site in all
sequenced clones. The methylation status of the MGMT
promoter region was then described as a data point in a
77-dimensional space constructed from the methylation
proportions of the 77 CpG sites. We performed a hier-
archical cluster analysis with the Ward method using
the raw methylation proportion without any standardiza-
tion to obtain a general view of the global methylation
features of the MGMT promoter region. The cases were
grouped into four clusters (Figure 1A). These clusters
were correlated with the degree of methylation. The col-
umn bars below the clustering indicate the MSP results
for 53 samples. Typical examples of qBGS results are
shown in Figure 2. The samples in cluster 1 were
strongly methylated, the samples in cluster 2 were mod-
erately methylated, the samples in cluster 3 were slightly
methylated, and the samples in cluster 4 were almostcluster 4 cluster 2
cluster p-value
1  vs 2 0.631
1  vs 3 0.276
1  vs 4 0.00491
2  vs 3 0.276
2  vs 4 0.0204







ised analysis based on the MGMT methylation patterns. (A) A
3 samples. Cluster 1 (Black), strongly methylated samples; cluster 2
4 (blue), mostly unmethylated. The columns below the clustering show
the white column is unmethylated samples. (B, C) Survival analysis
r PFS, the analysis showed statistically significant differences between
= 0.0204). For OS, there was no statistically significant difference
rd a difference between cluster 1 and cluster 4 (p = 0.0533).
Sample 29 (68 clones) (cluster 1)
Sample 10 (77 clones) (cluster 3) Sample31 (57 clones) (cluster 4)
Sample 46 (61 clones) (cluster 2)A B
C D
Figure 2 Methylation pattern obtained by qBGS. Methylation pattern observed using qBGS. The black and white circles indicate methylated
and unmethylated CpG sites, respectively. Horizontally, 77 CpG sites are aligned. Vertically, the sequencing results of individual clones are aligned.
(A) Sample 29 from cluster 1 of Figure 1; (B) sample 46 from cluster 2; (C) sample 10 from cluster 3; and (D) sample 31 from cluster 4.
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difference for OS between cluster 1 and cluster 4 (p =
0.0533) (Figure 1B). Statistically significant associations
with PFS were observed between clusters 1 and 4 (p =
0.00491) and between clusters 2 and 4 (p = 0.0204)
(Figure 1C). Several cases that were judged to be methyl-
ated (i.e., to have a good prognosis) by MSP belonged to
clusters 3 and 4 (Figure 1A). For example, samples 13
and 16 belonged to cluster 4; both showed four months
of PFS and were described as poor prognosis [2], but
were judged to be methylated and to have a good prog-
nosis by MSP.
To demonstrate an overview of the methylation status
of the MGMT promoter region, the averages of the
methylation proportions of the CpG sites are shown in
Figure 3. The promoter sequence may be divided into
three segments according to the methylation propor-
tions. The methylation level of the CpG sites in the mid-
dle segment, from CpG28 to CpG50, was lower than
that of the other segments (Figure 3). This area is lo-
cated just upstream of the transcription start site. We
performed univariate Cox proportional hazard analysis
of PFS to identify prognostically important CpG sites
using the methylation proportion as a continuous vari-
able. Based on an analysis using the 53 training samples,
the log-rank p values of 20 CpG sites were less than
0.05. These 20 selected CpG sites were CpG63 (p = 0.0056),
CpG64 (p = 0.0088), CpG77 (p = 0.010), CpG62 (p = 0.012),CpG56 (p = 0.012), CpG68 (p = 0.014), CpG11 (p = 0.023),
CpG65 (p = 0.025), CpG66 (p = 0.025), CpG59 (p = 0.027),
CpG8 (p = 0.028), CpG60 (p = 0.028), CpG10 (p = 0.030),
CpG7 (p = 0.034),CpG5 (p = 0.034), CpG61 (p = 0.035),
CpG54 (p = 0.038), CpG9 (p = 0.038), CpG47 (p = 0.047),
and CpG67 (p = 0.048). Almost all of the selected sites
were located at positions from CpG5 to CpG11 or from
CpG54 to CpG68 (black columns in Figure 3). However,
only five CpG sites were selected for OS under the same
condition: CpG8 (p = 0.039), CpG28 (p = 0.041), CpG56
(p = 0.041), CpG5 (p = 0.044), and CpG45 (p = 0.049)
(gray columns in Figure 3). Three CpG sites, CpG5,
CpG8, and CpG56, showed a correlation with OS and
PFS. All of the results of univariate Cox analysis are sup-
plied in Additional file 2 (PFS) and Additional file 3 (OS).
Shah et al. reported a similar comprehensive methylation
analysis [34]. Their numbering scheme of CpG sites corre-
sponds to the addition of twenty to our numbering
scheme of sites.
Diagnostic system for prognosis prediction using
quantitative methylation data
As described above, the prognostic significance of each
CpG site is limited, and it would be more effective to
combine the information from multiple CpG sites. One
approach is an unsupervised analysis, including a cluster
analysis, shown above. However, to construct a diagnos-
tic system, supervised learning is more appropriate.






Figure 3 Proportion of methylation status and survival analysis at each CpG site. Average of the methylation percentage of CpG sites. The
black and gray columns in the top panel indicate CpG sites with correlations with PFS and OS, respectively, that exceed the threshold (p < 0.05).
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the methylation status of the MGMT promoter region,
we constructed a diagnostic system to predict the thera-
peutic outcomes of GB patients based on the methyla-
tion proportion of CpG51 - CpG74. Because we
intended to use a next-generation sequencer for the val-
idation study, we selected the CpG sites to be examined
based on the read length restriction of the sequencer.
This diagnostic score was denoted as the M-score
(methylation score) and is defined as a weighted sum of
the methylation proportion as follows:




where ‘Ai’ is a regression coefficient deduced by univari-
ate Cox analysis of PFS at CpG site i and ‘Xi’ is the
methylation proportion at CpG site i. As described
above, a correlation between OS and the methylation
status was not clear in our patient population. We there-
fore used the same M-score calculation formula for OS
as well. First, the performance of the M-score diagnostic
system was evaluated by leave-one-out-cross-validation
(LOOCV) using the 53 training samples. The 53 samples
were divided into groups consisting of one and 52 sam-
ples, and ‘Ai’ was calculated by univariate Cox analysis
using the data for the remaining 52 samples. Thethreshold was selected from M-scores of the 52 samples
so that the log-rank p value of the Kaplan-Meier analysis
for the two divided groups was minimized. In cases of
multiple M-scores with the same minimum p value, the
median was selected as the threshold. Next, the M-score
of the one sample was calculated using parameters de-
duced from the 52 samples, and the sample was classi-
fied into either the good or poor prognosis group using
the threshold. This process was repeated until all sam-
ples were tested. The LOOCV procedure is schematic-
ally shown in Additional file 1: Figure S2. The results of
the LOOCV procedure are shown in Figure 4A and B;
this approach demonstrated excellent prognostic ability
with OS and PFS (OS, p = 0.0381; PFS, p = 0.00122).
Thus, the diagnostic accuracy of our system is better
than that of the MSP-based approach (Figure 4C, D)
(OS, p = 0.993; PFS, p = 0.113).
Validation of the diagnostic system using next-generation
sequencing
For validation of the test set, the parameters (Ai) were
calculated using all 53 samples in the training set, and
the threshold was set at 2.2, the average of the thresh-
olds of the 53 LOOCV processes.
For the 32 test set samples, we performed qBGS with
a next-generation sequencer, MiSeq, to examine the po-
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Figure 4 (See legend on next page.)
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Figure 4 Survival analysis of the training set by M-score and MSP. In each panel, the red line indicates either a good prognosis (M-score) or
the methylated (MSP) group. The black line indicates either a poor prognosis (M-score) or the unmethylated (MSP) group. (A) training set,
M-score, OS. (B) training set, M-score, PFS. (C) training set, MSP, OS. (D) training set, MSP, PFS. (E) test set, M-score, OS. (F) test set, M-score, PFS.
(G) test set, MSP, OS. (H) test set, MSP, PFS.
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of genomic DNA. The mean depth of MiSeq sequencing
was 80,817 reads. The methylation proportion of each
CpG site was obtained, M-scores were calculated, and
the test set samples were classified using the threshold
listed above. Survival analysis indicated a statistically sig-
nificant difference between the two groups with respect
to PFS (p = 0.0376) and OS (p = 0.0476) (Figure 4E, F).
There was no statistically significant difference between
the two groups by classification with MSP (OS, p = 0.326;
PFS, p = 0.342) (Figure 4G, H).
For potential future applications of this technique, we
designed PCR primers that amplify the same region from
FFPE samples. The method and results are shown in
Additional file 4.
Multivariate Cox regression analysis
We performed Cox regression analysis to evaluate clin-
ical parameters, such as age (above or below 60), gender,
the extent of resection, post-operative chemotherapy
(VAC-feron or TMZ), and the methylation status by the
M-score sequencing method as predictors of OS and
PFS in the GB patients in the test set. The variables with
a p value < 0.2 were analyzed with a backward stepwise
Multivariate Cox proportional hazard model. For OS,
the best predictor was the M-score (p = 0.0585) (Hazard
Ratio, 0.3558), and the next best prognostic factor was
the extent of surgical resection (p = 0.0739) (Hazard
Ratio, 0.5996). The M-score was found to be the best
predictor of PFS (p = 0.0247; Hazard Ratio, 0.334).
Discussion
In this report, we characterized the methylation status of
the entire MGMT promoter region using deep sequen-
cing. The methylation status of each CpG site was quan-
titatively evaluated by sequencing multiple clones. Based
on these results, we constructed a prognosis predictor
that incorporates the methylation status of multiple CpG
sites using supervised learning. The construction of a
classifier using supervised learning is popular in the field
of gene expression profiling, and we demonstrated here
that the same approach is effective for the prediction of
methylation status.
In our patient population, the correlation of the
methylation status with OS was less clear than that with
PFS. This is most likely due to variation of the therapy
used after the first line therapy. The majority of our pa-
tients received repeated surgical resections, second linechemotherapy or additional radiotherapy. For multivari-
ate analysis, age was not a prognosis factor, unlike in the
past reports. We also performed surgical medical treat-
ment with methylation-positive elderly patients. In par-
ticular, repeated surgery was likely to prolong the
survival time of the glioblastoma patients with a poor
prognosis.
MSP is the most widely used assay for methylation.
However, MSP can only detect the CpG sites in the pri-
mer region; the methylation status of other CpG sites
has no effect on the amplification. In a prior study, only
12.5% of the results obtained from two MSP experi-
ments matched when the forward and reverse primers
were different [35]. In addition, there is no established
method to confirm the quality of bisulfite-converted
genomic DNA. We assessed the quality using the Ct
value of actin in real-time PCR. Approximately 64% of
our glioma samples were methylation-positive with
MSP. The positive rate was higher than that in other
studies with some exceptions [36,37]. We excluded sam-
ples damaged by bisulfite treatment in the actin-based
confirmation system, and this process may have in-
creased the positive rate. This discrepancy in MSP re-
sults, which is most likely a false positive, might be
influenced by the T genotype of the MGMT C > T
(rs16906252) enhancer single-nucleotide polymorphism
(SNP), which was reported by McDonald et al. [38] to
interact with MGMT promotor methylation. Vlassen-
broeck et al. also evaluated the results of qMSP based
on the copy number of actin using real-time PCR [39]. It
is often difficult to set a threshold for agarose gel pat-
terns of MSP. This problem has been overcome by
quantitative MSP [40,41]. Quantitative MSP was applied
in two recent phase 3 trials of glioma [21,22]. However,
the problem of limited coverage of CpG sites by MSP re-
mains in need of technical improvements.
As discussed above, bisulfite sequencing can cover all
CpG sites. In this context, pyrosequencing is considered
to cover more CpG sites than MSP [26]. The methyla-
tion proportions can be semi-quantitatively deduced
from the peak height of each incorporated nucleotide.
The main disadvantage of pyrosequencing is its short read
length [25,26]. qBGS using Sanger sequencing is not sub-
ject to this limitation, and its moderate read depth pro-
vides more accurate quantitative information. Because
deep sequencing with the Sanger method is laborious, the
use of next-generation sequencing may make this ap-
proach more comparable to pyrosequencing.
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is the absence of a consensus regarding the data hand-
ling of multidimensional quantitative data. Dunn et al.
and Motomura et al. used the average of the methylation
proportion of multiple CpG sites (CpG51 - CpG62,
Dunn et al.; CpG2 - CpG16, Motomura et al.) [42,43].
Karayan-Tapon et al. used the methylation proportion of
five CpG sites (CpG 53–57) and grouped patients using
the median value of the methylation proportion as the
threshold [25]. We developed the M-score diagnostic
system using the analysis method of gene expression
profiling and calculated the optimized threshold by
LOOCV. The M-score is the weighted sum of the
methylation proportions of multiple CpG sites, which
maximizes the correlation with the survival time. Our
approach is more advanced than a simple summation of
the population of methylated sites, and adding data from
a larger patient population will improve the performance
of the predictor. Bady et al. examined the quantitative
value of 18 CpG sites in the MGMT promoter area using
the Infinium methylation BeadChip and revealed two
distinct CpG sites (CpG10 and CpG68). They converted
multidimensional data to one methylation probability
score using the inverse logit function. The classifier was
validated with an external data set [44]. Both studies in-
dicate a new direction for MGMT methylation assays
based on evaluation of multiple CpG sites.
Shah et al. also quantitatively evaluated the methyla-
tion of the MGMT promoter [34]. Although the number
of sequenced clones in that study was far less than that
of our study (median of 10 clones), their results were
similar to our results; the CpG sites located downstream
of the transcription start site were often correlated with
PFS. This prior study indicates that our observations are
likely to be universal, and suggests that our prognosis
predictor may be applicable to other patient populations.
The identification of biomarkers of gliomas has been
an active area of research in recent years. It is well
known that IDH mutations are a strong prognostic factor
[45]. IDH mutations are associated with a hypermethyla-
tion phenotype [46], suggesting that the methylation of
the MGMT promoter is one part of a genome-wide
methylation profile [47]. Based on qBGS analysis, we iden-
tified different extents of methylation of CpG sites in the
MGMT promoter region.
Recently, the methylation status of MGMT has be-
come a focal point in the management of elderly GB pa-
tients. Two MGMT methylation analyses using samples
from large phase 3 trials with elderly GB patients
demonstrated that TMZ monotherapy was superior to
conventional radiation therapy for the management of
MGMT-methylated GB patients. Conversely, TMZ mono-
therapy was inferior to radiation therapy in GB cases with
unmethylated MGMT [21,22]. These results indicate thatthe MGMT methylation status is a strong predictive factor
for the efficacy of TMZ monotherapy in elderly GB pa-
tients and that evaluating MGMT methylation status is
necessary for the management of these patients. The rela-
tionship between the efficacy of TMZ monotherapy and
qBGS-based methylation analysis of the MGMT promoter
in elderly GB merits further investigation.
In addition to its application for elderly patients, TMZ
monotherapy has been utilized for low-grade glioma pa-
tients [20,48]. In this group, the co-deletion of 1p19q
and IDH mutations were molecular prognostic factors.
Given the findings in elderly GB patients, the methyla-
tion status of the MGMT promoter may also predict the
outcomes of low-grade glioma patients treated by TMZ
monotherapy. Because the MGMT promoter in normal
tissue is generally unmethylated, methylated MGMT
cases are susceptible to contamination by normal tissue.
An advantage of qBGS is that it is easy to observe the
state of contamination. qBGS also revealed intratumoral
heterogeneity in the methylation of the MGMT pro-
moter, which should be considered when using other
methylation assays. Although qBGS is complicated and
time-consuming, it is an important process for evaluat-
ing the methylation features of the MGMT promoter.Conclusions
We constructed a novel diagnostic system to predict the
prognosis of glioblastoma patients using information re-
garding the methylation status of the entire MGMT pro-
moter region. A precise assessment of the methylation
status of the MGMT promoter may improve the predic-
tion of disease progression and assist in the choice of
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